Última actualización 12 de julio de 2026
Key finding
Total daily insulin dose was similar between treatments [10.7 (3.9) vs. 12.2 (5.3) units; p = 0.050]
This study evaluated ultra-rapid insulin lispro (URIL) compared to standard insulin lispro (IL) in closed-loop systems for type 1 diabetes, finding URIL improved glucose control metrics.
Quick read
The essential study design details in one scan.
EvidenceScore™
Moderate
Study type
RCTs
Follow-up
Short-Term (≤3 mo)
Risk of bias
Some Concerns
Guarda investigacion, organiza estudios y vuelve a encontrar evidencia importante rapidamente.
Plain-language summary
A plain-language read of the study’s main message and where it applies.
Study focus
This study evaluated ultra-rapid insulin lispro (URIL) compared to standard insulin lispro (IL) in closed-loop systems for type 1 diabetes, finding URIL improved glucose control metrics.
Improving glucose control is crucial for individuals with type 1 diabetes to reduce the risk of long-term complications. This study suggests that ultra-rapid insulin lispro could be a beneficial option, potentially leading to better management of blood sugar levels, although further research is needed to confirm these findings.
Statistical significance was not achieved for most outcomes. Sample size may limit the generalizability of the findings. The study did not measure long-term outcomes or complications.
Published in
Publication details and source links for this paper.
Hood T, Jonathan L, Malgorzata EW, Catherine F, Roman H, Lalantha L. Ultra-rapid insulin lispro improves glucose control in closed-loop systems for type 1 diabetes. Diabetic Medicine. 2025;42(10):e70122. doi:10.1111/dme.70122
URIL resulted in a higher percentage of time in range (49.3%) compared to IL (39.9%), p = 0.072.
URIL led to lower time spent in Level 1 hyperglycemia (50.7%) compared to IL (59.5%), p = 0.098.
Total daily insulin dose was similar between URIL (10.7 units) and IL (12.2 units), p = 0.050.
Evidence network
Understand where this research contributes within the broader evidence network.
This study contributes evidence to Insulin Lispro and Percentage of time spent above 10.0 mmol/L, Pre-meal mean glucose, Time above 13.9 mmol/L, and 2 more.
This study contributes evidence to
Primary intervention
Insulin Lispro
Primary outcomes
Evidence topics
Primary intervention
Intervention and outcome relationships this study adds to the evidence network.
Editorial context
See why this paper is useful beyond its individual results.
Evidence network role
This section describes how the study fits into the current evidence network. It does not determine whether an intervention works on its own.
1
Related topics
5
Evidence pairs
171
Related studies
Evidence topic
Contributes evidence
Guarda estudios y paginas de evidencia, organiza tu Evidence Tracker y manten en un solo lugar la investigacion que te importa.
Evidencia principal
Tema de evidencia
matched_outcome
Core evidence
The primary outcomes reported in this study.
Insulin Lispro → Percentage of time spent above 10.0 mmol/L
Insulin Lispro → Percentage of time spent above 10.0 mmol/L
Insulin Lispro → Time above 13.9 mmol/L
Insulin Lispro → Time above 13.9 mmol/L
Insulin Lispro → Total daily insulin dose
Insulin Lispro → Total daily insulin dose
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Evidence Library
Save research, organize studies, and quickly find important evidence again.
Explore related studies, evidence collections, and research questions.
Relationships organized using the Dediabetes Evidence Intelligence™ framework.
This study contributes to evidence on Insulin Lispro and Insulin Resistance, Insulin Lispro and CGM Time in Range.
This study contributes to the evidence on the following intervention-outcome relationships.
Medications
Medications
Curated evidence collections and hubs this study is part of.
All studies measuring CGM Time in Range
Measures CGM Time in Range as a key outcome.
All studies on Insulin Lispro
Contributes to Insulin Lispro evidence base.
All studies measuring Insulin Resistance
Measures Insulin Resistance as a key outcome.
Latest published studies
Published within the last 2 years.
Jump to pre-filtered views in Evidence Explorer.
1 results
1 results
1 results
1 results
1 results
Generated from the study's connected evidence using Evidence Intelligence™.
Current evidence does not show a clear benefit of Insulin Lispro for Percentage of time spent above 10.0 mmol/L.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Percentage of time spent above 10.0 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Insulin Lispro for Pre-meal mean glucose.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Pre-meal mean glucose
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Insulin Lispro for Time above 13.9 mmol/L.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time above 13.9 mmol/L
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Current evidence does not show a clear benefit of Insulin Lispro for Time in range.
ConsistencyScore™: Consistency cannot yet be determined from the available evidence.
Ranked evidence signals
Time in range
EvidenceScore™ Emerging | EvidenceScore™ 59.0 | neutral | ConsistencyScore™ Unclear | 1 study
Why this answer: This answer is based on a single supporting study.
Limitations
Next steps
Choose a next path through related evidence topics, Evidence Explorer views, and research summaries.
Open broader Evidence Explorer views for this relationship.
Read related research summaries.
Focused on evidence, not advertising.
Your data is always protected.
New studies added every day.
